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Detect Pathogens or Single-Nucleotide Polymorphisms
in Human Genomic Samples
Jasmine I. Daksis*, Glen H. Erikson
Ingeneus Research, Mississauga, Ontario, Canada
Human genomic samples are complex and are considered difficult to assay directly without denaturation or PCR amplification.
We report the use of a base-specific heteropolymeric triplex, formed by native duplex genomic target and an oligonucleotide
third strand probe, to assay for low copy pathogen genomes present in a sample also containing human genomic duplex DNA,
or to assay human genomic duplex DNA for Single Nucleotide Polymorphisms (SNP), without PCR amplification. Wild-type and
mutant probes are used to identify triplexes containing FVL G1691A, MTHFR C677T and CFTR mutations. The specific triplex
structure forms rapidly at room temperature in solution and may be detected without a separation step. YOYO-1, a fluorescent
bis-intercalator, promotes and signals the formation of the specific triplex. Genomic duplexes may be assayed homogeneously
with single base pair resolution. The specific triple-stranded structures of the assay may approximate homologous
recombination intermediates, which various models suggest may form in either the major or minor groove of the duplex. The
bases of the stable duplex target are rendered specifically reactive to the bases of the probe because of the activity of
intercalated YOYO-1, which is known to decondense duplex locally 1.3 fold. This may approximate the local decondensation
effected by recombination proteins such as RecA in vivo. Our assay, while involving triplex formation, is sui generis, as it is not
homopurine sequence-dependent, as are ‘‘canonical triplexes’’. Rather, the base pair-specific heteropolymeric triplex of the
assay is conformation-dependent. The highly sensitive diagnostic assay we present allows for the direct detection of base
sequence in genomic duplex samples, including those containing human genomic duplex DNA, thereby bypassing the
inherent problems and cost associated with conventional PCR based diagnostic assays.
Citation: Daksis JI, Erikson GH (2007) Heteropolymeric Triplex-Based Genomic AssayH to Detect Pathogens or Single-Nucleotide Polymorphisms in
Human Genomic Samples. PLoS ONE 2(3): e305. doi:10.1371/journal.pone.0000305
INTRODUCTION
Triplex nucleic acids have attracted attention due to their potential
regulation of DNA transcription, replication, recombination,
chromosome packing, and potential applications in gene therapy
[1–8]. The ‘‘canonical triplex’’ structures of these studies have
consisted of long stretches of uninterrupted homopyrimidine or
homopurine strands, typically 12–14 bases in length, that bind in
the major groove of duplex DNA, forming Hoogsteen or reverse
Hoogsteen hydrogen bonds with bases in the homopurine or
purine-rich strand of the duplex. Substantial deviations from strict
binding rules are understood to preclude triplex formation [9–13].
The utility of such ‘‘canonical triplexes’’ is severely limited due to
the requirement of long uninterrupted homopurine sequences in
the double-stranded DNA (dsDNA). Such sequence requirements
have been understood to preclude the development of triplex-
based molecular diagnostics.
The discovery that dsDNA targets, under readily achieved
conditions, may specifically bind third-strand DNA oligonucleotides
of any base sequence, was accordingly a significant advance [14].
Third-strand binding, facilitated and stabilized by YOYO-1,
a cationic bis-intercalator, occurs within 5 minutes at room
temperature with great facility, over a wide range of temperatures,
under mildand variedincubation conditionsand atphysiological pH.
Specific heteropolymeric triplex formation between non-denatured
dsDNA and a ssDNA of mixed base sequence can occur without
strand displacement, duplex invasion or the action of recombination
proteins, such as recA. This triplex binding capability was used to
demonstrate that the Triplex AssayH can accurately detect 1-, 2-, or
3-bp mutations, deletions or insertions in synthetic dsDNA targets
and in homozygous or heterozygous polymerase chain reaction
(PCR) amplified dsDNA amplicons of varied GC content [14].
PCR amplification based molecular diagnostics are not optimal,
due to complexity in optimization, inherent replication error rate,
risk of contaminant amplification and cost. The predictable and
unpredictable variables that negatively affect PCR amplification
based diagnostic methods in real world settings have been
recognized as significant [15,16]. In this report we disclose our
advances in SNP and pathogen detection in complex genomic
samples using the Triplex AssayH technology. We demonstrate the
Genomic AssayH, carried out homogeneously in bulk solution,
whereby SNPs or pathogens in samples containing human
genomic dsDNA are directly detected by fluorescent signal. We
do not have recourse to PCR amplification.
RESULTS
Genomic AssayH used to detect pathogens at low
copy number
Molecular diagnostic testing for infectious diseases, bacterial and
viral, commonly depend upon PCR based methodologies. High
copy numbers of the pathogen, such as 10
6 to 10
8 colony forming
units (CFU)/ml, may be required for successful PCR amplification
Academic Editor: Cecile Fairhead, Pasteur Institute, France
Received February 16, 2007; Accepted February 25, 2007; Published March 21,
2007
Copyright:  2007 Daksis, Erikson. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: Ingeneus Inc.
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: jasmine@ingeneus.net
PLoS ONE | www.plosone.org 1 March 2007 | Issue 3 | e305by diagnostic labs [16]. Use of the Genomic AssayH to detect
bacterial genomic dsDNA targets at low concentrations was
investigated.
Sequences of the ssDNA probes used are listed in Table 1.
Perfectly matched 25-mer triplexes formed in reaction mixtures
containing 100 copies of Bacillus globigii (BG) genomic dsDNA and
probe bglIR-WT25C (probe 1) during a 5 minute incubation in
the presence of 300 nM YOYO-1 (Figure 1). All incubations
referred to in this report were carried out at room temperature
(RT). Duplex DNA employed in our experiments was never
subjected to denaturing conditions. The perfect match reaction
mixture signal emission intensities were all significantly greater
than the combined fluorescence signals emitted by target BG
genomic dsDNA and YOYO-1 control intensities and probe and
YOYO-1 control intensities (Supplemental Table S1). BG
genomic dsDNA controls, which could not be detected at a 32%
PMT setting on the Genexus Analyzer, were however detected at
the more sensitive 36% PMT setting, consistent with the very low
copy number of BG genomic DNA being assayed. To identify
triplex-associated signal, all fluorescence emission values from
reaction mixtures were corrected for background fluorescence by
subtracting the appropriate probe control emission intensity. After
initial assay, emissions from all reactions were monitored over time
to obtain additional support for the diagnostic conclusions. The
efficiency of triplex formation slightly improved during the first
35 minutes of incubation and remained relatively constant
thereafter (Figure 1). Other BG genomic DNA samples were
prepared as 10-fold serial dilutions, ranging in amount from 10
6
copies to 10
2 copies. All were successfully detected using probe 1
and YOYO-1 (data not shown).
Even more remarkable was the ability of the Genomic AssayH to
specifically detect 100 copies of bacterial genomic DNA in
a sample also containing human genomic dsDNA. Heteropoly-
meric perfectly matched triplexes were detectably formed between
the 100 copies of BG genomic dsDNA and probe 1 in the presence
of 300 nM YOYO-1, 40 mM TMA-Cl and 2 ng (302 copies) of
human genomic dsDNA (hgDNA) (Figure 1). Moreover, periodic
monitoring showed there was a small, progressive increase in
triplex-associated fluorescence emission throughout the first
65 minutes of incubation. The fluorescence emissions of the
reaction mixtures, whose emissions are shown in Figure 1, were
also monitored after 24 hours of incubation. While the BG triplex-
associated fluorescence observed in the absence of background
hgDNA slightly decreased after 24 hours of incubation, the BG
triplex-associated fluorescence observed in the sample also
containing hgDNA continued to increase throughout the 24 hours
of incubation (Supplemental Table S1). It is noteworthy that the
Table 1. 25-mer and 15-mer ssDNA probe sequences.
......................................................................
Probe Name
Probe
No. Sequence
bglIR-WT25C 1 59-TATTTTGATTATAGGACATGAAGAT-39
DR01-WT15 2 59-GAGCCGAAGGGGCAG-39
CFTR delta F508-WT25C 3 59-TAGGAAACACCAAAGATGATATTTT-39
CFTR delta F508-MUT25C 4 59-ATAGGAAACACCA---ATGATATTTTCT-39
CFTR delta I507-WT25C 5 59-TAGGAAACACCAAAGATGATATTTT-39
CFTR delta I507-MUT25C 6 59-ATAGGAAACACCAAAGA---TATTTTCT-39
CFTR 3659delC-WT25C 7 59-TGGTTTGGTTGACTTGGTAGGTTTA-39
CFTR 3659delC-MUT25C 8 59-ATGGTTTGGTTGACTTG-TAGGTTTA-39
CFTR 3849+10kbCRT-
WT25C
95 9-GTGTCTTACTCGCCATTTTAATACT-39
CFTR 3849+10kbCRT-
MUT25C
10 59-GTGTCTTACTCACCATTTTAATACT-39
CFTR 2789+5GRA-WT25C11 59-AATAGGACATGGAATACTCACTTTC-39
CFTR 2789+5GRA-
MUT25C
12 59-AATAGGACATGGAATATTCACTTTC-39
CFTR G551D-WT25C 13 59-ATTCTTGCTCGTTGACCTCCACTCA-39
CFTR G551D-MUT25C 14 59-ATTCTTGCTCGTTGATCTCCACTCA-39
CFTR 621+1GRT-WT25C 15 59-AAGTATTACCTTCTTATAAATCAAA-39
CFTR 621+1GRT-MUT25C16 59-AAGTATTAACTTCTTATAAATCAAA-39
CFTR R1162X-WT25C 17 59-AACTTAAAGACTCGGCTCACAGATC-39
CFTR R1162X-MUT25C 18 59-AACTTAAAGACTCAGCTCACAGATC-39
CFTR 1717-1GRA-WT25C 19 59-TGGAGATGTCCTATTACCAAAAATA-39
CFTR 1717-1GRA-
MUT25C
20 59-TGGAGATGTCTTATTACCAAAAATA-39
CFTR A455E-WT25C 21 59-CCAGCAACCGCCAACAACTGTCCTC-39
CFTR A455E-MUT25C 22 59-CCAGCAACCTCCAACAACTGTCCTC-39
CFTR G542X-WT25C 23 59-ATTCCACCTTCTCCAAGAACTATAT-39
CFTR G542X-MUT25C 24 59-ATTCCACCTTCTCAAAGAACTATAT-39
CFTR N1303K-WT25C 25 59-TAGGGATCCAAGTTTTTTCTAAATG-39
CFTR N1303K-MUT25C 26 59-TAGGGATCCAACTTTTTTCTAAATG-39
CFTR R560T-WT25C 27 59-AGTTATTCACCTTGCTAAAGAAATT-39
CFTR R560T-MUT25C 28 59-AGTTATTCACGTTGCTAAAGAAATT-39
CFTR W1282X-WT25C 29 59-TTTCCTCCACTGTTGCAAAGTTATT-39
CFTR W1282X-MUT25C 30 59-TTTCCTTCACTGTTGCAAAGTTATT-39
MTHFR C677T-WT25C 31 59-TGATGATGAAATCGGCTCCCGCAGA-39
MTHFR C677T-MUT25C 32 59-TGATGATGAAATCGACTCCCGCAGA-39
FVL G1691A-WT25C 33 59-CCCTCTGTATTCCTCGCCTGTCCAG-39
FVL G1691A-MUT25C 34 59-CCCTCTGTATTCCTTGCCTGTCCAG-39
All 25-mer probes listed were antisense. Probe 2 was a sense 15-mer probe. The
site altered in the mutant probes is shown in bold and is underlined. Deletions
in the mutant probes are indicated by ‘‘dashes’’.
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Figure 1. Detection of Bacillus globigii genomic dsDNA at low copy
number. 100 copies of BG genomic dsDNA (0.46 pg) were reacted with
3.2 pmoles of 25-mer ssDNA probe in the presence of 0.56TBE, 40 mM
TMA-Cl, and 300 nM YOYO-1 in either the presence or absence of 2 ng
of human genomic dsDNA (approximately 302 copies). Fluorescent
emissions of the reaction mixtures (80 ml) were monitored with the
GenexusH Analyzer at a setting of 32% PMT after 5, 15, 25, 35, 45, 55
and 65 minutes of incubation at RT. Intensity of triplex-associated
fluorescence is plotted as a function of incubation time for the BG
triplexes formed in the presence of either 300 nM YOYO-1 (1) or 300 nM
YOYO-1 and human genomic dsDNA (2).
doi:10.1371/journal.pone.0000305.g001
Triplex-Based Genomic Assay
PLoS ONE | www.plosone.org 2 March 2007 | Issue 3 | e305triplex-associated fluorescence emission remained stable over an
extended incubation period of 24 hours. The ability to homoge-
neously assay 0.33 copies of bacterial genomic DNA for each copy
of hgDNA present in the sample demonstrates the extreme
sensitivity of the Genomic AssayH in detecting pathogens in 80 ml
bulk solution.
In this paper we present the use of the Genomic AssayH to
detect nucleic acid sequences in various types of samples.
Throughout, detection occurs by means of fluorescent emissions
from YOYO-1 molecules. The assay may be carried out
homogeneously, without a separation step because YOYO-1
molecules, when suitably stimulated, emit with varying intensities
dependent upon the nucleic acid structures with which they are
complexed and also dependent upon whether certain other
reagents are present at very low concentrations. In addition to
data in support of these previously unrecognized characteristics of
YOYO-1 emissions, we will below, under the ‘‘YOYO-1 emissions
examined’’ section of the Results, present data for the unexpected
observation that certain lesser concentrations of YOYO-1 will
emit much more brightly than greater concentrations of YOYO-1
in the presence of uniform concentrations of nucleic acid
oligonucleotides, short duplex DNA or human genomic dsDNA.
Genomic AssayH identifies 1 bp SNPs in drosophila
genomic dsDNA
The ability of the Genomic AssayH to identify 1 bp mismatches in
non-PCR amplified, non-denatured drosophila genomic dsDNA was
investigated. The drosophila genome was selected as an assay target
because its size at 165 million bp is greater than that of an average
human chromosome. The mutant drosophila genomic dsDNA (ts1
gDNA) contains a 1 bp A to T substitution within the erg gene (a
seizure locus) [17]. Similar mutations in the human erg gene (HERG)
cause long-QT syndrome, a type of cardiac arrhythmia [18].
The highest triplex-associated fluorescent emission intensity was
achieved when wild-type drosophila genomic dsDNA (wt gDNA) was
reacted with probe 2, indicating that heteropolymeric triplexes,
composed of genomic dsDNA bound to a ssDNA probe, can readily
form and easily be detected in a homogeneous bulk solution after just
5 min of incubation at RT (Figure 2). The fluorescent intensities
attributed to the wt gDNA and YOYO-1 control sample and the wt
ssDNA and YOYO-1 control sample were 12% and 1%, re-
spectively, of the total fluorescent intensity emitted from the sample
containing perfectly matched triplexes after 5 min of incubation.
When the maximum fluorescent emission values were corrected for
background fluorescence to account for triplex-associated fluorescent
emission, the mismatched dsDNA:ssDNA complexes containing
a 1 bp A-A mismatch (ts1 gDNA+probe 2) emitted a triplex-
associated fluorescent intensity that was 67% lower than the triplex-
associated fluorescent intensity emitted from the perfectly matched
dsDNA:ssDNA complexes (wt gDNA+probe 2) after 5 min of
incubation (Figure 2). A marginal increase in discrimination between
perfectly matched and 1 bp mismatched triplexes was observed upon
extended incubation, indicating that the matched triplex complexes
formed in the first 5 min, were stable throughout the 90 min
incubation period which was periodically monitored. These results
demonstrate that the YOYO-1 mediated Genomic AssayH can be
employed to assay for 1 bp SNPs in non-denatured genomes of the
complexity of drosophila, homogeneously in bulk solution.
Genomic AssayH identifies 1 bp CFTR SNPs and FVL
G1691A in human genomic dsDNA
The ability of the Genomic AssayH to identify clinically relevant
SNPs in the CFTR gene and the factor V gene in non-PCR
amplified, non-denatured human genomic dsDNA was investigat-
ed. The CFTR SNPs were chosen from the 25 most prevalent
CFTR mutations identified by the American College of Medical
Genetics based on data derived from Grody et al. [19]. The Factor
V Leiden (FVL) mutation, G1691A, results in the substitution of
glutamine for arginine at position 506 in the amino acid sequence
of the coagulation factor V protein [20]. FVL G1691A is a SNP
responsible for greater than 90 percent of inherited venous
thromboembolism attributed to mutations in factor V [21].
Typically the ssDNA probe controls produced higher levels of
fluorescent emission in the presence of YOYO-1 as compared to
that emitted from the genomic dsDNA target control comprising
an identical amount of YOYO-1. On occasion, significantly
different fluorescence emission levels were observed for the wild-
type and mutant ssDNA probe plus YOYO-1 controls, due to
different levels of self hybridization characteristic of various probe
sequences in the presence of YOYO-1. Data relevant to these
observations are set forth below in the ‘‘YOYO-1 emissions
examined’’ section of the Results.
30-mer, 25-mer, 20-mer and 15-mer ssDNA probe sequences
were tested for use in the Genomic AssayH (Supplemental Tables
S2 and S3). Surprisingly, 25-mer probes were empirically
determined to be optimal for maximum discrimination between
perfectly matched and 1 bp mismatched triplex-associated fluo-
rescent emissions when hgDNA was being assayed, under the
conditions of our testing. To identify triplex-associated signal,
fluorescence emission values from the reaction mixtures were
corrected for background fluorescence by subtracting the appro-
priate probe control emission value from the relevant reaction
mixture emissions, all emission intensities being acquired after
equal periods of incubation.
Heteropolymeric perfectly matched DNA triplexes in reaction
mixtures comprised of wild-type hgDNA and wild-type probe
Figure 2. Assay of drosophila genomic dsDNA for the ts1 mutation in
the erg gene. Fifty ng of either wild-type drosophila genomic dsDNA
(wt gDNA) or mutant drosophila genomic dsDNA (ts1 gDNA) were
reacted at RT for 5 min with 4 pmoles of wild-type probe 2 in the
presence of 0.56TBE and 500 nM YOYO-1. Fluorescent emissions of the
reaction mixtures (100 ml) were monitored with the GenexusH Analyzer
at a setting of 30% PMT after 5, 15, 30, 45, 60, 75 and 90 minutes of
incubation. The intensity of fluorescence is plotted as a function of
incubation time for each sample analyzed. The samples consist of
YOYO-1 only with no DNA present (1), wt gDNA with no added ssDNA
probe (2), ts1 gDNA with no added ssDNA probe (3), ssDNA probe 2 (4),
perfectly matched triplex (5) and 1 bp A–A mismatched triplex (6), as
indicated.
doi:10.1371/journal.pone.0000305.g002
Triplex-Based Genomic Assay
PLoS ONE | www.plosone.org 3 March 2007 | Issue 3 | e305delta F508-WT25C (probe 3), formed and were detected after as
little as a 5 min incubation in the presence of 600 nM YOYO-1
(Figure 3A and Table 2). It is truly remarkable that perfect match
triplex-associated emissions can be significantly greater than the
combined emissions of a hgDNA target control with YOYO-1 and
a probe control with YOYO-1 (Table 2). The percent variation of
triplex-associated fluorescence (TAF) signals was 0.2–5.0% when
triplicate samples prepared at the same time were assayed on the
same plate concurrently. The signal of perfect match triplex
formation increased dramatically during the first 15 min of
incubation, after which a plateau in fluorescence emission level
was observed (Figure 3A). The triplex-associated fluorescent
emissions produced by a 3 bp deletion triplex in reaction mixtures
comprising either 500 pg or 250 pg hgDNA and mutant probe
delta F508-MUT25C (probe 4) were 95% and 100% lower,
respectively, than those emitted by the perfectly matched triplexes
comprising comparable amounts of hgDNA and probe 4 after
5 min of incubation, and remained at this low level throughout the
75 min incubation period monitored (Figure 3A and Table 2).
When 1 ng of wild-type hgDNA was reacted with wild-type
probe 3659delC-WT25C (probe 7) in the presence of 500 nM
YOYO-1, triplex-associated signals were detected after 5 min of
incubation (Figure 3B). A slight increase in triplex-associated
fluorescence was observed over the 60 min of incubation. The
triplex-associated fluorescent emissions from a 1 bp deletion
triplex in a reaction mixture comprised of 1 ng hgDNA and
mutant probe 3659delC-MUT25C (probe 8) remained constant
throughout the 60 min incubation period and were 81% lower
than those emitted from the reaction mixture containing the
perfectly matched triplexes (Figure 3B).
The highest fluorescent emission intensity was achieved when
wild-type hgDNA was reacted with wild-type probe 2789+5GRA-
WT25C (probe 11), indicating perfect match triplex formation
after 5 min of incubation in the presence of 500 nM YOYO-1
(Figure 3C and Table 3). The emissions from these perfectly
matched DNA triplexes remained stable throughout the 60 min
incubation period. When 2 ng of hgDNA was reacted with mutant
probe 2789+5GRA-MUT25C (probe 12) to form a 1 bp T–G
mismatch triplex, the triplex-associated fluorescent emission was
100% lower than that emitted by the reaction mixture containing
the perfectly matched triplex after 5 min incubation and remained
constant thereafter (Figure 3C and Table 3). In this instance the
fluorescent emissions from reaction mixtures containing mis-
matched genomic DNA triplexes were less than the emissions from
the comparable probe and YOYO-1 control. We hypothesize that
this result occurs because, while YOYO-1 facilitates and signals
Figure 3. Assay of CFTR and FVL mutations in human genomic dsDNA. Human genomic dsDNA was extracted from blood (A, B and D) or saliva (C)
as described in the text. (A) 500 pg of wild-type human genomic dsDNA (approximately 75 copies) was reacted at RT with 3.2 pmoles of either wild-
type or mutant ssDNA probe in the presence of 0.56TBE and 600 nM YOYO-1. (B–D) 1 ng, 2 ng or 200 pg of wild-type human genomic dsDNA
(approximately 151 copies, 302 copies or 30 copies, respectively) was reacted at RT with 3.2 pmoles of either wild-type or mutant ssDNA probe in the
presence of 0.56TBE and 500 nM YOYO-1. (A–D) Reaction mixtures (80 ml) were irradiated as described in the text and analyzed for fluorescent
emission. The intensity of triplex-associated fluorescence is plotted as a function of incubation time for each sample analyzed. The samples consisto f
perfectly matched triplex (1) and mismatched triplex (2) as indicated for CFTR delta F508 (A), CFTR 3659delC (B), CFTR 2789+5GRA (C) and FVL
G1691A (D).
doi:10.1371/journal.pone.0000305.g003
Triplex-Based Genomic Assay
PLoS ONE | www.plosone.org 4 March 2007 | Issue 3 | e305self-association of the 25-mer probes when no genomic dsDNA is
present, such self-associated probe complexes tend to disperse,
along with any complexed YOYO-1, upon introduction of the
genomic target and that only a small offsetting gain in fluorescence
occurs when YOYO-1 intercalates into the duplex genomic target
or into imperfect triple stranded structures. When emissions from
samples containing mismatched triplexes are less intense than
emissions from the relevant probe and YOYO-1 control, very
desirable assay conditions have been achieved.
Heteropolymeric perfectly matched triplexes were detected in
reaction mixtures containing either 2 ng, 1 ng, 500 pg or 200 pg
hgDNA and probe FVL G1691A-WT25C (probe 33), formed
during a 5 min incubation in the presence of 500 nM YOYO-1
(Figure 3D and Supplemental Table S4). The perfect match
triplex signal levels were all significantly greater than the combined
fluorescence signals of target amounts of hgDNA with YOYO-1
control and wild-type probe with YOYO-1 control (Supplemental
Table S4). As was usual, the triplex-associated emissions from the
reaction mixtures were stable throughout the 60 min incubation
period. The triplex-associated fluorescent emissions from reaction
mixtures containing between 2 ng and 200 pg of genomic target
and probe FVL G1691A-MUT25C (probe 34) and producing
1 bp G–T mismatched triplexes were consistently less than probe
34 plus YOYO-1 control values after 5, 15, 30, 45 and 60 minute
incubations (Supplemental Table S4). Therefore the reactions
produced no detected triplex-associated fluorescence. Comparable
results were observed when 500 pg, 200 pg, 100 pg or 75 pg of
hgDNA were reacted with 3.2 pmoles of either wild-type probe
Table 2. Triplex assays of human genomic dsDNA for CFTR delta F508 (3 bp AAG deletion).
..................................................................................................................................................
Sample
Fluorescence on
Genexus argon
laser @ PMT 34
after 5 min TAF
% of difference
relative to
perfect match
TAF
Fluorescence on
Genexus argon
laser @ PMT 34
after 15 min TAF
% of difference
relative to
perfect match
TAF
1) YOYO-1 (600 nM) 0 0
2) delta F508-WT25C (3.2 pmole) (antisense) 7650 6326
3) delta F508-MUT25C (3.2 pmole) (antisense) 7626 7123
4) wt gDNA (500 pg) 2985 3041
5) wt gDNA (500 pg)+delta F508-WT25C (perfect) 19688 12038 26578 20252
6) wt gDNA (500 pg)+delta F508-MUT25C (3 bp AAG del) 8211 585 295.1 7211 88 299.5
7) wt gDNA (250 pg) 1110 1097
8) wt gDNA (250 pg)+delta F508-WT25C (perfect) 12176 4526 11348 5022
9) wt gDNA (250 pg)+delta F508-MUT25C (3 bp AAG del) 7097 ,0 2100 6399 ,0 2100
Sample
Fluorescence on
Genexus argon
laser @ PMT 34
after 30 min
TAF % of difference
relative to
perfect match
TAF
Fluorescence on
Genexus argon
laser @ PMT 34
after 45 min
TAF % of difference
relative to
perfect match
TAF
1) YOYO-1 (600 nM) 0 0
2) delta F508-WT25C (3.2 pmole) (antisense) 5716 5555
3) delta F508-MUT25C (3.2 pmole) (antisense) 7135 7167
4) wt gDNA (500 pg) 3035 2977
5) wt gDNA (500 pg)+delta F508-WT25C (perfect) 26488 20772 26065 20510
6) wt gDNA (500 pg)+delta F508-MUT25C (3 bp AAG del) 6935 ,0 2100 6744 ,0 2100
7) wt gDNA (250 pg) 1064 1096
8) wt gDNA (250 pg)+delta F508-WT25C (perfect) 11525 5809 11142 5587
9) wt gDNA (250 pg)+delta F508-MUT25C (3 bp AAG del) 6151 ,0 2100 6008 ,0 2100
Sample
Fluorescence on
Genexus argon
laser @ PMT 34
after 60 min
TAF % of difference
relative to
perfect match
TAF
Fluorescence on
Genexus argon
laser @ PMT 34
after 75 min
TAF % of difference
relative to
perfect match
TAF
1) YOYO-1 (600 nM) 0 0
2) delta F508-WT25C (3.2 pmole) (antisense) 5147 4943
3) delta F508-MUT25C (3.2 pmole) (antisense) 6978 7097
4) wt gDNA (500 pg) 2912 2831
5) wt gDNA (500 pg)+delta F508-WT25C (perfect) 25064 19917 25091 20148
6) wt gDNA (500 pg)+delta F508-MUT25C (3 bp AAG del) 6402 ,0 2100 6180 ,0 2100
7) wt gDNA (250 pg) 1013 989
8) wt gDNA (250 pg)+delta F508-WT25C (perfect) 10407 5260 9974 5031
9) wt gDNA (250 pg)+delta F508-MUT25C (3 bp AAG del) 5723 ,0 2100 5531 ,0 2100
The target was human genomic dsDNA, wild-type for CFTR. The 25-mer probes were delta F508-WT25C (wild-type) and delta F508-MUT25C (mutant). 600 nM YOYO-1
was present in each sample. TAF indicates Triplex-Associated Fluorescence.
doi:10.1371/journal.pone.0000305.t002
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PLoS ONE | www.plosone.org 5 March 2007 | Issue 3 | e305CFTR 2789+5GRA-WT25C (probe 11) or mutant probe CFTR
2789+5GRA-MUT25C (probe 12) (Supplemental Table S5).
These results collectively demonstrate the high level of efficiency
and specificity of the Genomic AssayH when practised in bulk
solutionwith25-merssDNAprobesandYOYO-1,todirectlydetect
mismatches between probes and non-denatured, non-amplified
human genomic dsDNA targets, over a broad range of genomic
target concentrations. SNPs in human genomic targets ranging
from 4 ng to 75 pg, approximately 604 copies to 11 copies, were
identified in the Genomic AssayH using varied YOYO-1 concen-
trations, homogeneously and in an 80 ml solution.
The human genomic DNA samples assayed in Figures 3A, 3B
and 3D were purified from blood. We assayed for the CFTR
2789+5GRA mutation in both human genomic dsDNA purified
from blood (Supplemental Table S6) and purified from treated
saliva/sputum samples (Figure 3C and Table 3), which had been
stored at RT for 1 week following incubation at 50uC for 30 min.
The 50uC incubation is recommended by the manufacturer of the
Oragene oral sample acquisition kit to allow long-term storage at
RT. In side by side comparisons, triplex-associated fluorescent
emissions from the reaction mixtures containing hgDNA purified
from blood or from treated saliva/sputum, indicated that perfectly
matched triplexes formed with equivalent efficiency after 5 min
incubation in the presence of 500 nM YOYO-1 (Table 3 and
Supplemental Table S6). The triplex-associated emissions re-
mained stable throughout a 60 min incubation during which they
were monitored. The triplex-associated fluorescent emissions from
reaction mixtures containing 1 bp T-G mismatched triplexes were
very low, regardless of the origin of the sample or which of the two
methods of purification of the sample had been employed (Table 3
and Supplemental Table S6).
This demonstrates that the Genomic AssayH of hgDNA purified
from saliva/sputum in the Oragene DNA collection kit can be as
efficient and specific as one in which the hgDNA is purified from
blood. Purification of genomic DNA, as occurs when using Qiagen
kits, is therefore not a requirement for the Genomic AssayH of
samples containing hgDNA. The acquisition of hgDNA for
molecular assay from oral samples offers clear advantages in cost,
handling, storing and shipping over acquisition of samples from
blood. It would also be greatly preferred by sample donors. It
therefore opens the way for convenient point of care testing
employing the Genomic AssayH. In side by side comparisons, 1 ml
of peripheral blood, purified by Qiagen kit, yielded more than
enough human genomic DNA to perform over 9,000 assays as
described herein, if 1 ng were assayed per reaction. A typical
saliva/sputum sample, purified with an Oragene kit, produced
enough human genomic DNA for over 7,000 assays, if 1 ng were
needed per reaction.
Genomic AssayH identifies MTHFR C677T in
homozygous and heterozygous human genomic
dsDNA samples
The ability of the Genomic AssayH to identify the methylenete-
trahydrofolate reductase (MTHFR) mutation, C677T, in non-PCR
amplified, non-denatured, human genomic dsDNA was investi-
Table 3. Triplex assays of human genomic dsDNA (purified from saliva) for CFTR 2789+5GRA (1 bp T–G mismatch).
..................................................................................................................................................
Sample
Fluorescence on
Genexus argon
laser @ PMT 30
after 5 min TAF
% of difference
relative to
perfect match
TAF
Fluorescence on
Genexus argon
laser @ PMT 30
after 15 min TAF
% of difference
relative to
perfect match
TAF
1) YOYO-1 (500 nM) 0 0
2) 2789+5GRA-WT25C (3.2 pmole) (antisense) 23291 22608
3) 2789+5GRA-MUT25C (3.2 pmole) (antisense) 22804 22071
4) wt gDNA (4 ng) 1530 1856
5) wt gDNA (4 ng)+2789+5GRA-WT25C (perfect) 44651 21360 43624 21016
6) wt gDNA (4 ng)+2789+5GRA-MUT25C (1 bp T-G) 23893 1089 294.9 23531 1460 293.1
7) wt gDNA (2 ng) 21 19
8) wt gDNA (2 ng)+2789+5GRA-WT25 (perfect) 38650 15359 38142 15534
9) wt gDNA (2 ng)+2789+5GRA-MUT25 (1 bp T–G) 22453 ,0 2100 22430 359 297.7
Sample
Fluorescence on
Genexus argon
laser @ PMT 30
after 30 min
TAF % of difference
relative to
perfect match
TAF
Fluorescence on
Genexus argon
laser @ PMT 30
after 45 min
TAF % of difference
relative to
perfect match
TAF
1) YOYO-1 (500 nM) 0 0
2) 2789+5GRA-WT25C (3.2 pmole) (antisense) 22243 21877
3) 2789+5GRA-MUT25C (3.2 pmole) (antisense) 21847 21714
4) wt gDNA (4 ng) 1959 2102
5) wt gDNA (4 ng)+2789+5GRA-WT25C (perfect) 42950 20707 42412 20535
6) wt gDNA (4 ng)+2789+5GRA-MUT25C (1 bp T–G) 23077 1230 294.1 22806 1092 293.8
7) wt gDNA (2 ng) 18 18
8) wt gDNA (2 ng)+2789+5GRA-WT25 (perfect) 37707 15464 37351 15474
9) wt gDNA (2 ng)+2789+5GRA-MUT25 (1 bp T–G) 21835 ,0 2100 21541 ,0 2100
The target was human genomic dsDNA, wild-type for CFTR. The 25-mer probes were 2789+5GRA-WT25C (wild-type) and 2789+5GRA-MUT25C (mutant). 500 nM
YOYO-1 was present in each sample. TAF indicates Triplex-Associated Fluorescence.
doi:10.1371/journal.pone.0000305.t003
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PLoS ONE | www.plosone.org 6 March 2007 | Issue 3 | e305gated. The MTHFR 677 polymorphism is a cytosine to thymine
substitution in the sense strand of the MTHFR gene, resulting in an
alanine to valine substitution in the MTHFR enzyme [22].
Different fluorescence emission levels were observed for the
wild-type probe MTHFR C677T-WT25C (probe 31) plus
YOYO-1 control and the mutant probe MTHFR C677T-
MUT25C (probe 32) plus YOYO-1 control, due to differences
in levels of self hybridization which are characteristic of each
probe sequence in the presence of YOYO-1 (Supplemental Tables
S7 and S8). To identify triplex-associated signal, fluorescence
emission values from the reaction mixtures, containing hgDNA,
probe and YOYO-1, were corrected for background fluorescence
by subtracting the appropriate probe control emission value from
the relevant reaction mixture emission, both of which were
measured after the same duration of incubation.
Perfectly matched DNA triplexes in reaction mixtures com-
prised of either wild-type homozygous hgDNA and wild-type
probe MTHFR C677T-WT25C (probe 31) or mutant homozy-
gous hgDNA and mutant probe MTHFR C677T-MUT25C
(probe 32), formed efficiently and were detected after just 5 min of
incubation in the presence of 500 nM YOYO-1 (samples 1 and 4,
respectively, in Figure 4). The efficiency of matched triplex
formation, signaled by the appearance of triplex-associated
fluorescence, was slightly greater in the reaction mixtures
comprising 1 ng mutant homozygous hgDNA and mutant probe
32, than that comprising 1 ng wild-type homozygous hgDNA and
wild-type probe 31, after 5 min of incubation. The triplex-
associated fluorescent emission intensities observed from reaction
mixtures containing either of the two perfectly matched triplexes
were more similar when 2 ng, instead of 1 ng, of hgDNA was
present in the 80 ml bulk solution reaction mixtures (Supplemental
Tables S7 and S8).
When 1 ng mutant heterozygous hgDNA was reacted with
mutant probe 32 (sample 3, Figure 4), the triplex-associated
fluorescent emissions were 77% less after 5 min incubation and
90% less after 60 min incubation, than those emitted from the
reaction mixture containing the perfectly matched triplexes
comprised of 1 ng wild-type homozygous hgDNA and wild-type
probe 31 (sample 1, Figure 4), each evaluated after comparable
periods of incubation.
The triplex-associated fluorescent emissions from 1 bp C–A
mismatch triplexes in a reaction mixture comprised of 1 ng wild-
type homozygous hgDNA and mutant probe 32 (sample 2,
Figure 4) were 92% less after 5 min and 98% less after 60 min
incubation, than those emitted from the reaction mixture
containing the perfectly matched triplexes comprised of 1 ng
wild-type homozygous hgDNA and wild-type probe 31 (sample 1,
Figure 4), each evaluated after comparable periods of incubation.
The triplex-associated fluorescent emissions from 1 bp C–A
mismatch triplexes in a reaction mixture comprised of 1 ng
mutant homozygous hgDNA and wild-type probe 31 (sample 5,
Figure 4) were consistently less than the wild-type probe 31 plus
YOYO-1 control value. Therefore the reaction produced no
detected triplex-associated fluorescence.
These results demonstrate the high efficiency and specificity of
the Genomic AssayH in assaying for SNPs in wild-type
homozygous, mutant heterozygous or mutant homozygous
hgDNA samples homogeneously and in bulk solution. The results
shown were obtained using antisense 25-mer wild-type and mutant
probes for MTHFR C677T. Comparable results were observed
when analogous reactions were performed using sense 25-mer
wild-type and mutant probes for MTHFR C677T (data not
shown). The sensitivity of the Genomic AssayH to assay for
MTHFR C677T was further demonstrated when human genomic
dsDNA targets, ranging in weight from 2 ng to 200 pg, were
successfully assayed with wild-type probe 31 and mutant probe 32
in a final reaction volume of 80 ml (Supplemental Table S9).
Numerous SNPs, in regions having widely disparate GC
contents, have been successfully and repeatedly assayed in hgDNA
using the Genomic AssayH (Table 4). On occasion, variations in
reagent concentrations or protocol were advantageous. The
triplex-associated fluorescent emissions observed from the mis-
matched triplexes varied between 100% to 54% lower than those
observed from the respective perfectly matched triplexes after
5 min of incubation (Table 4).
The Genomic AssayH can employ the waxing and/or
waning of triplex-associated fluorescent emissions
The effect of addition of various kosmotropic agents to the
reaction mixture when assaying to identify various SNPs in human
genomic dsDNA was investigated. In the presence of 40 mM of
the kosmotropic cation, tetramethylammonium chloride (TMA-
Cl), the fluorescent emissions from the wild-type probe CFTR
3849+10kbCRT-WT25C (probe 9) and mutant probe CFTR
3849+10kbCRT-MUT25C (probe 10) controls were very similar
(Supplemental Table S10). Duplicate triplex reaction mixtures
were assembled. In one instance YOYO-1 was added last, with the
mixture incubated for 5 min before irradiation (Figure 5A). In the
other instance all components of the reaction mixture (except
hgDNA) had been mixed, incubated for 5 min and irradiated once
before hgDNA was added, followed by a further 5 min incubation
and another irradiation (Figure 5B). To identify triplex-associated
emissions, fluorescence emission values from the reaction mixtures
were corrected for background fluorescence by subtracting the
appropriate probe control emission values from the relevant
reaction mixture emissions, all of which were acquired after
comparable periods of incubation.
Figure 4. Assay of MTHFR C677T in homozygous and heterozygous
human genomic dsDNA samples. Human genomic dsDNA that was
either wild-type homozygous, mutant heterozygous or mutant
homozygous with respect to MTHFR C677T, was extracted from blood
as described in the text. One ng of human genomic dsDNA
(approximately 151 copies) was reacted at RT with 3.2 pmoles of either
wild-type or mutant ssDNA probe in the presence of 0.56TBE and
500 nM YOYO-1. Reaction mixtures (80 ml) were irradiated as described
in the text and analyzed for fluorescent emission. The intensity of
triplex-associated fluorescence is plotted as a function of incubation
time for each sample analyzed. The samples consist of perfectly
matched triplexes (1 and 4), mutant heterozygous triplexes (3) and
mismatched triplexes (2 and 5) as indicated for MTHFR C677T.
doi:10.1371/journal.pone.0000305.g004
Triplex-Based Genomic Assay
PLoS ONE | www.plosone.org 7 March 2007 | Issue 3 | e305The triplex-associated fluorescent emissions from perfectly
matched triplexes in reaction mixtures consisting of hgDNA and
wild-type probe 3849+10kbCRT-WT25C (probe 9), monitored
after a 15 min incubation in the presence of 40 mM TMA-Cl and
500 nM YOYO-1, were similar, whether YOYO-1 or hgDNA
had been added last to the reaction mixtures (Figures 5A and 5B).
Under both protocols, the perfectly matched triplex-associated
fluorescent emissions increased when monitored over the first
60 min of incubation.
In the reaction mixture containing 40 mM TMA-Cl, to which
YOYO-1 had been added last, the triplex-associated emissions
from 1 bp A–C mismatched triplexes, consisting of hgDNA and
mutant probe 3849+10kbCRT-MUT25C (probe 10), were 70%
less after 5 min of incubation and were 100% less after 30 min of
incubation, than those emitted from a similarly monitored reaction
mixture containing the perfectly matched triplexes (Figure 5A).
The triplex-associated emissions from the 1 bp A–C mismatched
triplexes in these reaction mixtures remained constant between
30 min and 60 min of incubation. In the reaction mixture
containing 40 mM TMA-Cl, to which hgDNA had been added
last, the triplex-associated emissions from 1 bp A–C mismatched
triplexes consisting of hgDNA and mutant probe
3849+10kbCRT-MUT25C (probe 10) were 49% less after
15 min of incubation and were 88% less after 60 min of
incubation, than those emitted from a similarly monitored reaction
mixture containing the perfectly matched triplexes (Figure 5B).
These results demonstrate that the addition of 40 mM TMA-Cl
to the triplex reaction mixture can result in an enhanced
progressive increase in triplex-associated fluorescent emission
levels from perfectly matched triplexes and an enhanced pro-
gressive decrease in triplex-associated fluorescent emission levels
from mismatched triplexes, which pattern of emission changes we
refer to as ‘‘waxing and waning’’. Increases in discrimination levels
between perfect match binding and mismatch binding can be
observed over time. A pronounced waxing and waning emission
pattern was also observed in Genomic AssaysH of hgDNA samples
for CFTR 2789+5GRA, CFTR delta F508 or FVL G1691A
detection when 45 mM TMA-Cl, 40 mM TMA-Cl or both
50 mM TMA-Cl and 20 mM NaCl were included, respectively, in
the reaction mixtures containing 500 nM YOYO-1 (data not
shown).
Numerous kosmotropic cations have been used by us in
conjuction with YOYO-1 to generally improve the specificity of
the Genomic AssayH and to enhance the waxing and waning of
triplex-associated emissions during SNP detection (data not
shown). These include 50 to 80 mM NaCl, 10 to 60 mM Na2SO4,
50 mM Na2HPO4, 125 to 250 mM (NH4)2SO4, 30 mM TriMA-
Cl, 30 to 52.5 mM TMA-Cl, each added separately, or 50 mM
TMA-Cl in combination with 10 to 20 mM NaCl. The benefits of
adding one or more kosmotropic cations to a Genomic AssayH
reaction mixture and the best concentrations for addition under
any set of selected assay conditions must be determined
experimentally.
YOYO-1 emissions examined
YOYO-1 will intercalate into a variety of multi-stranded nucleic
acid complexes. It is fluorescent when intercalated and suitably
irradiated. In the Genomic AssayH we used it to promote and
signal the formation of heteropolymeric, specific triplex useful in
diagnostics and analysis. As shown throughout this paper, the
emissions from YOYO-1 complexed in triple stranded structures
were detectable over and above the emissions generated by
YOYO-1 complexed with genomic duplex DNA present in the
reaction mixture and very significant emissions by YOYO-1
complexed with probe:probe binding. Our triplex assay reaction
mixtures typically contained concentrations of between 300 to
600 nM YOYO-1 when assaying genomic samples. We conclude
that YOYO-1 allowed for such assaying because it did not produce
a constant emission per intercalated molecule. Triplex intercalated
YOYO-1’s fluoresced much brighter than did duplex intercalated
YOYO-1’s. We also observed that YOYO-1 molecules were much
Table 4. Data from Assays of Human Genomic DNA Samples.
..................................................................................................................................................
Mutation Source Number of tests
Percentage GC in probe
sequence
Percentage difference of mismatched TAF
relative to perfect match TAF
CFTR delta F508 blood 102 28% 2100% to 281%
CFTR delta I507 blood 6 28% 2100% to 285%
CFTR 3659delC blood 11 40% 2100% to 255%
CFTR 3849+10kbCRT blood 9 36% 2100% to 282%
CFTR 2789+5GRA blood 16 36% 2100% to 275%
CFTR 2789+5GRA saliva 13 36% 2100% to 266%
CFTR G551D blood 11 48% 2100% to 261%
CFTR 621+1GRT blood 5 20% 2100% to 257%
CFTR R1162X blood 6 44% 267% to 236%
CFTR 1717-1GRA blood 12 32% 2100% to 258%
CFTR A455E blood 9 60% 2100% to 289%
CFTR G542X blood 6 36% 2100% to 260%
CFTR N1303K blood 8 32% 2100% to 283%
CFTR R560T blood 6 28% 2100% to 254%
CFTR W1282X blood 14 36% 2100% to 274%
MTHFR C677T blood 55 52% 2100% to 272%
FVL G1691A blood 34 60% 2100% to 281%
TAF indicates Triplex-Associated Fluorescence.
doi:10.1371/journal.pone.0000305.t004
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PLoS ONE | www.plosone.org 8 March 2007 | Issue 3 | e305brighter when intercalated into complexes of identical short
oligonucleotides, such as the probes used in our assay, than when
a like number of YOYO-1 molecules were in the presence of
genomic duplex DNA.
Probe:probe associated fluorescence constituted the major
source of unwanted background signal in our YOYO-1 promoted
triplex assay conducted homogeneously in solution. Such probe:p-
robe complex emissions were quantified in the ‘‘probe plus
YOYO-1’’ control which accompanied each triplex assay.
Emissions from probe:probe complexes must be determined
individually, as each probe base sequence has a characteristic
ability to not only form hairpin structures and self-dimer
hybridized complexes, but also to form parallel homologous
structures stabilized and signalled by intercalated YOYO-1
molecules (Daksis and Erikson, unpublished observations).
YOYO-1’s non-specific intercalation into duplex genomic DNA
also produced unwanted background signal in our assay, albeit of
a vastly lesser intensity than that emitted from YOYO-1s
intercalated into probe:probe complexes. This observation was
unexpected, but consistently observed. We investigated such
background emissions by having a ‘‘duplex target plus YOYO-
1’’ control which accompanied each triplex assay. Fortunately, the
signal emitted from triple-stranded nucleic acids and complexed
YOYO-1 molecules was so intense, that the triple-stranded
structure could be readily detected homogeneously in solution.
When genomic dsDNA was added last to a reaction mixture, we
believe probe:probe complexes dissolved and intercalated YOYO-
1 molecules were released.
To demonstrate YOYO-1’s ability to promote and signal the
formation of probe:probe complexes, we monitored fluorescent
emissions from 80 ml final volume hybridization mixtures contain-
ing 0.56TBE, pH 8.3, 40 mM TMA-Cl, 3.2 pmole of 25-mer
heteropolymeric DNA oligo probe bglIR-WT25C (probe 1) and
various concentrations of YOYO-1, ranging from 50 nM to
1000 nM, at 50 nM intervals. There was no emission from
YOYO-1 over this range of concentrations, if no nucleic acid was
present. The emissions were acquired at various time points after
commencement of incubation, ranging from 5 minutes to
24 hours using the GenexusH Analyzer. Supplemental Figure S1
showed the 5 minute, 65 minute and 24 hour emissions as
a function of YOYO-1 concentration.
At concentrations between 50 and 350 nM, YOYO-1 facilitated
probe:probe structures which formed by the 5 minute time point
and were stable thereafter for at least 24 hours, as indicated by
near uniform fluorescent emissions. At concentrations between
350 and 900 nM, YOYO-1 facilitated and signalled probe:probe
structures which appeared to dissipate over time. At concentra-
tions of 900 nM YOYO-1 or more, probe:probe complexes
appeared not to occur, or fluorescent emission from such
complexes was abolished, should they have formed. After 24 hours
of incubation, concentrations of 700 nM YOYO-1 or more
appeared to abolish probe:probe complexes, or emissions from
them, should they have remained. We speak in absolute terms for
convenience and to express the general meaning of our data. We
do not suggest that better instrumentation or more precise
experiments will not generate data, which will, at the margin,
qualify our statements.
The Supplemental Figure S1 data will be very disturbing, if
one’s only experience with intercalators has been to use a fixed
amount of intercalator to quantitate an unknown amount of
duplex DNA. In addition to the non-linear, fluorescence pattern
alluded to above, it is as well surprising that a lesser quantity of
YOYO-1 might fluoresce more brightly than a greater quantity
in the presence of a constant amount of DNA. Nevertheless, it was
an observable, highly reproducible and hence incontrovertible
result.
The maximum fluorescent emission in the presence of
3.2 pmoles of probe oligos arose when 100 nM of YOYO-1 was
present. Molecules of YOYO-1 intercalated with duplex genomic
DNA, as shown below, did not emit very intensely per molecule, as
compared to those intercalated in probe:probe complexes. The
inference may be fairly drawn that slight amounts of YOYO-1
complexed with homologously paired probes in a triplex assay test
mixture will produce unwanted background emissions which may
be significantly more intense than emissions from like amounts of
YOYO-1 intercalated with duplex genomic DNA. Such probe:p-
robe associated emissions will tend to minimize the triplex-
associated fluorescence (TAF) which can only be ascertained after
subtraction of the corresponding ‘‘probe plus YOYO-1’’ control
emission value. So as to not double count YOYO-1 background
emissions, we arrived at TAF by subtracting from the total
emission from the reaction mixture the concurrently acquired
‘‘probe plus YOYO-1’’ control emission intensity, while not
subtracting the ‘‘target plus YOYO-1’’ control emission intensity.
Figure 5. Waxing and waning of triplex-associated fluorescent
emissions can enhance a homogeneous in solution assay. (A, B)
Human genomic dsDNA was extracted from blood as described in the
text. Two ng of wild-type human genomic dsDNA (approximately 302
copies) was reacted at RT with 3.2 pmoles of either wild-type or mutant
ssDNA probe in the presence of 0.56TBE, 40 mM TMA-Cl and 500 nM
YOYO-1. (A) YOYO-1 was added last to the reaction mixtures. (B) Human
genomic dsDNA was added last to the reaction mixtures. (A, B) Reaction
mixtures (80 ml) were irradiated as described in the text and analyzed
for fluorescent emission. The intensity of triplex-associated fluorescence
is plotted as a function of incubation time for each sample analyzed.
The samples consist of perfectly matched triplex (1) and mismatched
triplex (2) as indicated for CFTR 3849+10kbCRT.
doi:10.1371/journal.pone.0000305.g005
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PLoS ONE | www.plosone.org 9 March 2007 | Issue 3 | e305The data presented in Supplemental Figure S1 was obtained
from a reaction mixture containing 40 mM TMA-Cl, a kosmo-
tropic cation. Supplemental Figure S2 compared YOYO-1
emissions acquired after 5 minutes of incubation in the presence
or absence of 40 mM TMA-Cl, when constant amounts of the
DNA oligo probes were present and concentrations of YOYO-1
varied. TMA-Cl is a water structuring agent. It is understood to
co-ordinate and bind multiple water molecules. Supplemental
Figure S2 disclosed some other surprising results.
The presence of TMA-Cl in the concentration employed,
facilitated a smooth and largely uninterrupted decline in YOYO-1
emissions from reaction mixtures containing increasing YOYO-1
concentrations, greater than 100 nM. Absent TMA-Cl, the
reaction mixtures exhibited a constant low level of YOYO-1
emission at YOYO-1 concentrations of 400 nM or more,
suggesting the absence of probe:probe complexes in the presence
of those concentrations of YOYO-1 or the inability of those
concentrations of intercalated YOYO-1s to emit light upon
irradiation. It is surprising that a low concentration of TMA-Cl
could have such a striking effect on YOYO-1 emissions and/or
probe:probe complex formation in the presence of an over-
whelming greater number of water molecules. From this data it
appeared that, absent TMA-Cl, YOYO-1, at concentrations
above 400 nM, disrupted the ability of probes to bind one another
homologously to create an anhydrous environment hospitable to
YOYO-1 intercalation and hence YOYO-1 emissions.
Supplemental Figure S3 displayed 5 minute incubation data
from reaction mixtures, with and without 40 mM TMA-Cl, where
3.2 pmoles of dsDNA bglIR probes were incubated with YOYO-1
concentrations from 50 nM to 1000 nM, at 50 nM intervals. The
dsDNA probes were comprised of antisense probe 1 and
a complementary 25-mer antiparallel sense strand to which it
was annealed in the presence of 100 mM NaCl. Here the objective
was to plot the emissions from varying YOYO-1 concentrations
present with a defined amount of identical short duplex DNA. The
data for the 65 minute incubation time point in each experiment
were virtually identical and the 24 hour time point data were
similar in each experiment. In Supplemental Figure S3 we saw, as
we did with the experiments with ssDNA oligo probes, that
maximal emission levels occurred, surprisingly, with low YOYO-1
concentrations present and hence low levels of YOYO-1 in-
tercalation. At increasing YOYO-1 concentrations above 200 nM,
TMA-Cl facilitated a steady, essentially linear, decline in emission
intensities. This decline was unexpected. We did not conclude that
the short duplexes were saturated in the presence of 200 nM
YOYO-1. In the reaction mixtures without TMA-Cl, increasing
YOYO-1 concentrations from 50 to 150 nM YOYO-1 resulted in
increased emissions but there was an abrupt emission decline when
concentrations between 200 and 300 nM YOYO-1 were present,
and in the presence of yet greater YOYO-1 concentrations,
declining emissions were produced.
Supplemental Figure S4 disclosed data from experiments where
reaction mixtures, with and without 40 mM TMA-Cl, contained
2 ng purified human genomic duplex DNA (gDNA). Concentra-
tions of YOYO-1 varying from 50 to 1000 nM, at 50 nM intervals
were added. The Supplemental Figure S4 data was obtained after
5 minutes of incubation. The 5 minute emission intensities from
reaction mixtures containing various concentrations of YOYO-1
were virtually identical at the 24 hour time point (data not shown).
In the presence of TMA-Cl, the data generally indicated
emissions, whose intensities increased, more or less linearly, by
about 50% over the tested range of increasing YOYO-1
concentrations. In the absence of TMA-Cl, the emissions from
a constant amount of human gDNA in the presence of increasing
YOYO-1 concentrations above 200 nM, tended to decrease at
a generally linear way. This data too would not be expected by
anyone conversant with using a constant amount of intercalating
dye to quantitate an unknown amount of duplex DNA. It showed
how TMA-Cl, at slight concentration, may affect emission from
duplex intercalated YOYO-1s. All of the foregoing data provides
much to be pondered. Almost nothing related to YOYO-1
emissions from low concentrations appears to occur as one would
expect. Fortunately, in spite of all this, YOYO-1 makes possible
a homogeneous triplex SNP assay of duplex genomic DNA sample
which is directly detectable.
Supplemental Figure S5 disclosed data from reaction mixtures
in which perfect or 1 bp mismatch triplexes were formed using our
standard 3.2 pmole/80 ml concentration of 25-mer oligo probes
and 2 ng of wild-type human genomic dsDNA, 40 mM TMA-Cl
and 600 nM YOYO-1. To identify triplex-associated emissions,
fluorescence emission values from the reaction mixtures were
corrected for background fluorescence by subtracting the ‘‘probe
plus YOYO-1’’ control emission intensities acquired at the
incubation time points at which reaction mixture emissions were
also acquired. The emission values giving rise to Supplemental
Figure S5 data are produced in Supplemental Table S11. The
data disclosed that the triplex-associated emissions of the
mismatched triplex, under the conditions of the reaction, were
less than that of the matched triplex. Supplemental Figure S6
presented the triplex-associated emissions from triplex assay
mixtures when 500 nM YOYO-1 and 45 mM TMA-Cl were
present. The emission values giving rise to Supplemental Figure S6
are produced in Supplemental Table S12. Supplemental Figure S6
disclosed very significant TAF single base pair assay discrimina-
tion, far in excess of that produced when 600 nM YOYO-1 and
40 mM TMA-Cl concentrations were used. This data disclosed
that YOYO-1 concentration must be matched with other reagents
present in the reaction mixture to carry out optimally sensitive and
optimally signalled triplex SNP assays of genomic samples
employing YOYO-1 as the promoter and reporter of the assay.
All such matching must be explored empirically.
The foregoing provides data disclosing some of the puzzling but
adventitious aspects of YOYO-1 emissions. Complexed YOYO-1
emissions can be remarkably intense at very dilute concentration
which may contribute high non-specific background emissions.
YOYO-1 emission variability produced by the class of nucleic acid
complex into which it is intercalated makes possible a very
sensitive and homogeneous assay for the presence of low copy
pathogens or SNPs in human genomic samples. It is of great
importance to realize that the YOYO-1 emission per molecule is
immensely variable depending on the nucleic acid structure into
which it is intercalated, and depends as well upon relative and
local YOYO-1 and reagent concentrations. It is readily apparent
that the YOYO-1 promoted and signalled triplex assay is
a phenomenon strongly related to hydration because kosmotropic
agents, such as TMA-Cl, can contribute very significantly to the
TAF. YOYO-1 causes whatever nucleic acids are present and
capable of providing multi-stranded anhydrous environments for
YOYO-1 intercalation, to set up in 5 minutes or less at room
temperature and thereafter to remain remarkably stable.
Discussion
Molecular diagnostics of nucleic acids currently rely almost
exclusively on a PCR amplification step. Due to the complexity
of PCR optimization, the risk of contaminant amplification, the
presence of known or unknown PCR inhibitors in reaction
mixtures, and the inherent replication error rate, the potential for
misdiagnosis when using PCR based diagnostic methodologies is
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adds to the cost of using the PCR method.
The well known sequence requirements of ‘‘canonical triplex’’
formation have been heretofore understood to preclude de-
velopment of molecular diagnostic methods whereby base pairs
in stable heteropolymeric duplex samples may be assayed with
base specific resolution using third strand probes.
We have developed a Genomic AssayH providing direct
detection of heteropolymeric triplex formation between native
genomic dsDNA and ssDNA probes, which eliminates reliance on
PCR amplification of genomic samples. The Genomic AssayH
results presented here clearly demonstrate the capability to assay
human genomic dsDNA homogeneously, in solution, at RT, after
as little as 5 minutes of incubation, using unlabeled ssDNA probes
and YOYO-1. Such heteropolymeric triplexes can be formed to
detect sequences, SNPs, deletions, insertions and repeated
sequences in genomic samples, or to detect the presence or
genotype of another organism or pathogen in a sample also
containing human genomic dsDNA. The assay provides for the
direct detection of a signal related to the base specific triplex
complex formed by the duplex target sequence and probe in
a homogeneous solution.
The Genomic AssayH reported herein depends upon YOYO-1
bis-intercalation rendering the duplex target into a locally de-
condensed conformation [23], which allows for specific base
recognition and detectable binding to occur between a hetero-
polymeric base sequence of a strand in the duplex and the
heteropolymeric base sequence of the probe strand. The Ingeneus
TriplexH and the Genomic AssayH are therefore conformation
dependent, whereas the ‘‘canonical triplex’’ is homopurine or
homopyrimidine sequence dependent. The base specific hetero-
polymeric triplex assay we report is therefore sui generis. The base
specific heteropolymeric complex formed in the assay reported
here approximates the triple strand intermediates which are
postulated by various models of homologous recombination.
Homologous recombination in vivo requires the action of
recombination proteins, such as RecA, to locally de-condense
the duplex so as to facilitate specific heteropolymeric recognition
and binding of the mixed base third strand. RecA’s effect on
binding duplex is to locally de-condense the duplex 1.5 fold
[24,25]. YOYO-1, which is a non-specific bis-intercalator as used
by us, is known to locally de-condense the duplex 1.3 fold [23]
upon intercalation. We accordingly propose that YOYO-1 causes
duplex DNA to be rendered into a conformation suitable for the
specific recognition and binding of a heteropolymeric probe strand
to a sequence of bases present in the duplex target.
There are two models of homologous recombination which seem
relevant to the understanding of the Genomic AssayH and the base
specific Ingeneus TriplexH upon which it depends. The model first
proposedinvolvesthirdstrandrecognitionofduplexbasesequencein
the major groove of the duplex [26]. That model has been elaborated
since [27–29]. The other model involves third strand recognition of
duplex base sequence in the minor grove of the duplex [30]. Our
references regarding each of the two homologous recombination
models referred to are representative only and are not exhaustive of
the groups working on such models and their published results.
In most cases, the triplex-associated fluorescent emission signal
we observe could be detected within the first 5 min of incubation
(Figures 1–5). While triplex-associated fluorescent emissions from
homogeneous reaction mixtures containing perfectly matched
genomic triplexes were relatively high, the triplex-associated
fluorescent emissions from reaction mixtures comprising mis-
matched triplexes were lower and could be very low (Figures 2–5
and Tables 2–4). The triplex-associated fluorescent emissions
observed from SNP assay mismatched triplexes were often between
80% to 100% less than those observed from the respective perfectly
matched triplexes. The observation that the emissions attributable
to triplex complexes formed with hgDNA samples after 5 min of
incubation, and were stably detected throughout extended incuba-
tions, strongly suggests that equilibrium of triplex formation had
been substantially achieved after only five min of incubation at RT.
Timeconstraints imposed by manual handling steps have precluded
our monitoring of emissions attributable to triplex formation after
incubations shorter than 5 min.
Reaction mixtures and protocols can be selected in which
changes in fluorescent emission levels between perfect match
triplexes and mismatch triplexes can allow for better discrimina-
tion based upon ‘‘waxing and waning’’ of emitted signals
monitored over time. The waxing and waning emission pattern
may be enhanced by the addition of selected concentrations of one
or more kosmotropic cations, added separately or in combination,
to an assay reaction mixture (Figure 5 and data not shown).
Additionally, there are advantages in carrying out assays in
duplicate employing varied protocols or reagents, so as to obtain
signals whose respective characteristics confirm the scoring of the
sample. When assaying genomic targets, it is very useful to have
fluorescence based methods, which are not dependent merely on
relative strength of emission intensities, but which also encompass
rates and direction of change of emissions over time.
The use of mathematical models to understand the thermody-
namics and kinetics of matched and mismatched duplex
hybridization, as time and concentration dependent, has recently
been reported [31]. Transitory phases in which mismatched
duplexes are initially more numerous than matched duplexes are
theorized with mismatched duplexes disassociating as the reaction
mixture comes to equilibrium. Our waxing and waning methods
are congruent with such observations and theorizing.
The Genomic AssayH can be very efficient and specific,
regardless whether YOYO-1 or genomic dsDNA has been added
last to the reaction mixtures (Figures 5A and 5B). This will allow
the Genomic AssayH to be carried out using kits containing all
reagents specific for the assay to be conducted, to which the test
genomic dsDNA is added last.
It is remarkable how easily 25-mer heteropolymeric specific
triplexes form in the presence of YOYO-1 and that they may be
directly and homogeneously detected in a reaction mixture
containing human genomic dsDNA. The number of YOYO-1
molecules present in a typical Genomic AssayH reaction mixture as
presented in this report is limiting and the number of potential
binding sites in a human genomic target is in excess, as is the
potential of ssDNA oligonucleotide probes to form parallel
homologous complexes stabilized and signaled by intercalated
YOYO-1s (Daksis and Erikson, unpublished observations). Upon
introduction of human genomic dsDNA to a reaction mixture
containing YOYO-1 and ssDNA oligonucleotide probes, it
appears that YOYO-1 intercalation into duplex DNA and
matched triplexes is favoured over YOYO-1 interaction with
probe:probe complexes. It is possible that the greatly increased
fluorescence emitted by perfectly matched triplex structures,
detectable above the YOYO-1 emission from genomic dsDNA
background, may be a result of mutual donor:donor energy
migration between stimulated YOYO-1 molecules incorporated in
the enhanced anhydrous conditions of the triplex structure.
The Genomic AssayH may also be performed with labels other
than YOYO-1 used free in solution, or in formats other than in
bulk solution (Daksis and Erikson, unpublished observations).
In conclusion, we have developed a rapid, homogeneous assay
based on detectable heteropolymeric triplex formation between
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recourse to PCR amplification based methods. The Genomic
AssayH allows the direct detection of low copy pathogen genomes
present in a sample also containing human genomic duplex DNA,
or the direct detection of SNPs in human genomic duplex DNA.
Our assay constitutes a hybridization assay which is fundamentally
different than all previously developed hybridization assays, since
no denaturation of the duplex DNA is required prior to binding of
the ssDNA probe. Furthermore, the presence of long stretches of
homopurine or homopyrimidine sequences in the binding region
of the duplex DNA, as necessary for ‘‘canonical triplex’’
formation, is not required in our assay. Provided a suitable local
de-condensation of the duplex target is achieved, specific
heteropolymeric triplexes readily form with third strand probes
with base pair resolution. The Genomic AssayH herein presented
depends upon YOYO-1, a bis-intercalator, to both de-condense
the duplex and to signal the presence of the specific triplex of the
assay. The heteropolymeric triplexes promoted by YOYO-1
approximate the heteropolymeric homologous recombination
triplex intermediates, which occur in vivo under the action of
recombination proteins, such as RecA. Homologous recombina-
tion models propose that mixed base ssDNA sequences bind either
in the major or minor groove of the duplex. It is accordingly no
longer necessary to denature genomic duplex DNA to be able to
assay it for the presence of a sequence of interest or a SNP, nor is it
necessary to perform a separation step if one wishes to employ
optical signals to assay a highly complex target in bulk solution.
MATERIALS AND METHODS
Single-stranded oligonucleotide probes
Sequences of the ssDNA probes used are listed in Table 1. All
oligonucleotide probes were synthesized on a DNA synthesizer,
cartridge purified and dissolved in ddH2O at a concentration of
1 pmole/ml. Probe 1 was complementary to a segment of the sense
strand of the Bgl I restriction endonuclease (bglIR) gene in Bacillus
globigii [32]. Probe 2 was complementary to a segment of the
antisense strand of the erg gene in Drosophila melanogaster [17].
Probes 3 to 30 were derived from various exons and/or introns of
the human cystic fibrosis transmembrane conductance regulator
gene (CFTR) [33]. Probes 31 and 32 were derived from exon 4 of
the human methylenetetrahydrofolate reductase (MTHFR) gene
[22]. Probes 33 and 34 were derived from exon 10 of the human
factor V gene [20].
Genomic sample isolation
Bacillus globigii (BG) genomic dsDNA was isolated from lysed
vegetative BG cells using a QIAamp DNA blood mini-purification
kit as per the manufacturer’s instructions (Qiagen, Mississauga,
Canada). Drosophila genomic dsDNA was purified from Drosophila
wild-type Canton-S and mutant sei
ts1 strains by multiple phenol-
chloroform extractions and kindly provided by Dr. Barry
Ganetzky (University of Wisconsin, Madison, WI, USA). Human
genomic dsDNA was extracted from human blood using
a QIAamp DNA blood purification kit (Qiagen, Mississauga,
Canada) or from human saliva using an Oragene DNA collection
kit (DNA Genotek, Ottawa, Canada) as per the manufacturers’
instructions. The concentration of each genomic dsDNA sample
was determined by UV spectroscopy.
Genomic AssayH
Different concentrations of genomic dsDNA were assayed,
dependent on the source of genomic DNA. Unless otherwise
indicated, the triplex binding reaction mixtures (80 ml) contained
the following: between 4 ng and 75 pg of human genomic dsDNA,
3.2 pmoles of 25-mer ssDNA probe, 22.5 mM Tris-borate,
pH 8.3, 0.5 mM EDTA (0.56TBE) and 500 nM YOYO-1.
YOYO-1, a hydrophobic bis-intercalator quenched by aqueous
medium, was supplied by Molecular Probes (Eugene, Oregon,
USA). Following a 5 min incubation at room temperature (RT)
(22uC), the reaction mixtures were placed into separate wells of
a Corning No Bind Surface 384-well plate (black with clear
bottom, with universal lid) and irradiated through the bottom of
the multi-well plate by the GenexusH Analyzer. The GenexusH
Analyzer employs a Melles Griot 15 mW argon ion laser, Model
35-IMA-415-120, configured to deliver about 84 W/cm
2/sec
radiation at a wavelength of 488 nm to each sample. The
GenexusH Analyzer, manufactured by Biomedical Photometrics
Inc. (Waterloo, Ontario, Canada), utilizes Macroview software,
which controls the scanning parameters of the confocal laser and
provides quantitative analysis of scanned samples in the multi-well
plates. Irradiation occurred at a sampling interval of 60 microns at
settings of 20 hertz, 30–34% PMT and 10 mA/V sensitivity. At
these scanning parameters, approximately 44,000 pixel emissions
were measured per assay and averaged. Fluorescent emissions
were also monitored over time. The GenexusH Analyzer allows
384 test samples to be scanned in approximately 2 min. Care must
be taken in selecting means of stimulating YOYO-1 emission.
YOYO-1 acts as a photocleavage agent if stimulated with overly
energetic radiation. We have empirically determined that light-
emitted diode (LED) irradiation, or laser irradiation of 84 W/
cm
2/sec can be optimal. Instruments powered by ‘‘bright light’’
sources, such as Xenon bulbs, that generate pulsed or continuous
bright light, which is subsequently filtered, have not proved useful
to carry out the Triplex AssayH using YOYO-1.
SUPPORTING INFORMATION
Figure S1. Fluorescence emissions from varied YOYO-1
concentrations and a 25-mer ssDNA probe. 3.2 pmoles of a 25-
mer ssDNA probe was reacted with various concentrations of
YOYO-1, ranging from 50 nM to 1000 nM, at 50 nM intervals,
in the presence of 0.56TBE and 40 mM TMA-Cl. Fluorescent
emissions of the reaction mixtures (80 ul) were monitored with
the Genexus Analyzer at a setting of 32% PMT after 5, 15, 25, 35,
45, 55 and 65 minutes, and 24 hours of incubation at RT.
Intensity of fluorescence is plotted as a function of YOYO-1
concentration for the probe:probe complexes formed after 5 min
of incubation (1), 65 min of incubation (2) or 24 hours of
incubation (3).
Found at: doi:10.1371/journal.pone.0000305.s001 (0.01 MB
PDF)
Figure S2. Comparison of the fluorescence emissions from
varied YOYO-1 concentrations and a 25-mer ssDNA probe in the
presence or absence of a kosmotropic agent. 3.2 pmoles of a 25-
mer ssDNA probe was reacted with various concentrations of
YOYO-1, ranging from 50 nM to 1000 nM, at 50 nM intervals,
in the presence of 0.56TBE, and in the presence or absence of
40 mM TMA-Cl. Fluorescent emissions of the reaction mixtures
(80 ul) were monitored with the Genexus Analyzer at a setting of
32% PMT after 5, 15, 25, 35, 45, 55 and 65 minutes, and
24 hours of incubation at RT. Intensity of fluorescence is plotted
as a function of YOYO-1 concentration for the probe:probe
complexes formed after 5 min of incubation in the presence (1) or
absence (2) of 40 mM TMA-Cl.
Found at: doi:10.1371/journal.pone.0000305.s002 (0.01 MB
PDF)
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varied YOYO-1 concentrations and a 25-mer dsDNA in the
presence or absence of a kosmotropic agent. 3.2 pmoles of a 25-
mer dsDNA was reacted with various concentrations of YOYO-1,
ranging from 50 nM to 1000 nM, at 50 nM intervals, in the
presence of 0.56TBE, and in the presence or absence of 40 mM
TMA-Cl. Fluorescent emissions of the reaction mixtures (80 ul)
were monitored with the Genexus Analyzer at a setting of 32%
PMT after 5, 15, 25, 35, 45, 55 and 65 minutes, and 24 hours of
incubation at RT. Intensity of fluorescence is plotted as a function
of YOYO-1 concentration for the dsDNA:YOYO-1 complexes
formed after 5 min of incubation in the presence (1) or absence (2)
of 40 mM TMA-Cl.
Found at: doi:10.1371/journal.pone.0000305.s003 (0.01 MB
PDF)
Figure S4. Comparison of the fluorescence emissions from
varied YOYO-1 concentrations and human genomic dsDNA in
the presence or absence of a kosmotropic agent. Human genomic
dsDNA was extracted from blood as described in the text. Two ng
of wild-type human genomic dsDNA (approximately 302 copies)
was reacted with various concentrations of YOYO-1, ranging
from 50 nM to 1000 nM, at 50 nM intervals, in the presence of
0.56TBE, and in the presence or absence of 40 mM TMA-Cl.
Fluorescent emissions of the reaction mixtures (80 ul) were
monitored with the Genexus Analyzer at a setting of 32% PMT
after 5, 15, 25, 35, 45, 55 and 65 minutes, and 24 hours of
incubation at RT. Intensity of fluorescence is plotted as a function
of YOYO-1 concentration for the dsDNA:YOYO-1 complexes
formed after 5 min of incubation in the presence (1) or absence (2)
of 40 mM TMA-Cl.
Found at: doi:10.1371/journal.pone.0000305.s004 (0.01 MB
PDF)
Figure S5. Assays of human genomic dsDNA for CFTR
3849+10kbCRT (1 bp A–C mismatch) in the presence of
600 nM YOYO-1 and 40 mM TMA-Cl. Human genomic
dsDNA was extracted from blood as described in the text. Two
ng of wild-type human genomic dsDNA (approximately 302
copies) was reacted at RT with 3.2 pmoles of either wild-type or
mutant ssDNA probe in the presence of 0.56TBE, 40 mM TMA-
Cl and 600 nM YOYO-1. YOYO-1 was added last to the reaction
mixtures. Reaction mixtures (80 ul) were irradiated as described in
the text and analyzed for fluorescent emission. The intensity of
triplex-associated fluorescence is plotted as a function of in-
cubation time for each sample analyzed. The samples consist of
perfectly matched triplex (1) and mismatched triplex (2) as
indicated for CFTR 3849+10kbCRT.
Found at: doi:10.1371/journal.pone.0000305.s005 (0.01 MB
PDF)
Figure S6. Assays of human genomic dsDNA for CFTR
3849+10kbCRT (1 bp A–C mismatch) in the presence of
500 nM YOYO-1 and 45 mM TMA-Cl. Human genomic
dsDNA was extracted from blood as described in the text. Two
ng of wild-type human genomic dsDNA (approximately 302
copies) was reacted at RT with 3.2 pmoles of either wild-type or
mutant ssDNA probe in the presence of 0.56TBE, 45 mM TMA-
Cl and 500 nM YOYO-1. YOYO-1 was added last to the reaction
mixtures. Reaction mixtures (80 ul) were irradiated as described in
the text and analyzed for fluorescent emission. The intensity of
triplex-associated fluorescence is plotted as a function of in-
cubation time for each sample analyzed. The samples consist of
perfectly matched triplex (1) and mismatched triplex (2) as
indicated for CFTR 3849+10kbCRT.
Found at: doi:10.1371/journal.pone.0000305.s006 (0.01 MB
PDF)
Table S1. Assays of Bacillus globigii genomic dsDNA in the
presence or absence of 2 ng human genomic dsDNA. 100 copies
of Bacillus globigii genomic dsDNA are detected by triplex assay in
reaction mixtures containing 300 nM YOYO-1 in the presence or
absence of 2 ng human genomic dsDNA.
Found at: doi:10.1371/journal.pone.0000305.s007 (0.05 MB
DOC)
Table S2. Comparison of triplex assays of human genomic
dsDNA using 15-mer, 20-mer or 25-mer ssDNA probes. Triplex
assays of human genomic dsDNA for CFTR delta F508 using 15-
mer, 20-mer or 25-mer ssDNA probes demonstrate optimal probe
length under the conditions employed, to be 25 bases.
Found at: doi:10.1371/journal.pone.0000305.s008 (0.06 MB
DOC)
Table S3. Comparison of triplex assays of human genomic
dsDNA using 20-mer, 25-mer or 30-mer ssDNA probes. Triplex
assays of human genomic dsDNA for MTHFR C677T using 20-
mer, 25-mer or 30-mer ssDNA probes demonstrate optimal probe
length under the conditions employed, to be 25 bases.
Found at: doi:10.1371/journal.pone.0000305.s009 (0.06 MB
DOC)
Table S4. Assays of varying concentrations of human genomic
dsDNA for Factor V Leiden (1 bp G–T mismatch). The specificity
of the triplex assay in detecting FVL G1691A in mismatched
triplexes is demonstrated over a broad range of human genomic
dsDNA concentrations.
Found at: doi:10.1371/journal.pone.0000305.s010 (0.07 MB
DOC)
Table S5. Assays of varying concentrations of human genomic
dsDNA for CFTR 2789+5GRA (1 bp T–G mismatch). The
specificity of the triplex assay in detecting CFTR 2789+5GRAi n
mismatched triplexes is demonstrated over a broad range of
human genomic dsDNA concentrations.
Found at: doi:10.1371/journal.pone.0000305.s011 (0.08 MB
DOC)
Table S6. Assays of human genomic dsDNA (purified from
blood) for CFTR 2789+5GRA (1 bp T–G mismatch). The
specificity of the triplex assay in detecting CFTR 2789+5GRA
in mismatched triplexes comprising human genomic dsDNA
purified from blood is demonstrated.
Found at: doi:10.1371/journal.pone.0000305.s012 (0.04 MB
DOC)
Table S7. Assays of human genomic dsDNA (wild-type
homozygous or mutant heterozygous samples purified from blood)
for MTHFR C677T. The specificity of the triplex assay in
assaying wild-type homozygous and mutant heterozygous human
genomic dsDNA samples for MTHFR C677T is demonstrated.
Found at: doi:10.1371/journal.pone.0000305.s013 (0.06 MB
DOC)
Table S8. Assays of human genomic dsDNA (mutant homozy-
gous sample purified from blood) for MTHFR C677T. The
specificity of the triplex assay in assaying mutant homozygous
human genomic dsDNA samples for MTHFR C677T is
demonstrated.
Found at: doi:10.1371/journal.pone.0000305.s014 (0.05 MB
DOC)
Table S9. Assays of varying concentrations of human genomic
dsDNA for MTHFR C677T (1 bp C–A mismatch). The specificity
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triplexes is demonstrated over a broad range of human genomic
dsDNA concentrations.
Found at: doi:10.1371/journal.pone.0000305.s015 (0.07 MB
DOC)
Table S10. Assays of human genomic dsDNA employing
varying protocols. The specificity of the triplex assay in detecting
CFTR 3849+10kbCRT in mismatched triplexes is demonstrated
in reaction mixtures containing a kosmotropic agent. Two reaction
protocols are compared.
Found at: doi:10.1371/journal.pone.0000305.s016 (0.05 MB
DOC)
Table S11. Assays of human genomic dsDNA for CFTR
3849+10kbCRT (1 bp A–C mismatch) in the presence of
600 nM YOYO-1 and 40 mM TMA-Cl. The emission values
giving rise to Supplementary Figure S5 data are shown. The
specificity of the triplex assay in detecting CFTR 3849+10kbCRT
in mismatched triplexes is demonstrated in reaction mixtures
containing 600 nM YOYO-1 and 40 mM TMA-Cl.
Found at: doi:10.1371/journal.pone.0000305.s017 (0.05 MB
DOC)
Table S12. Assays of human genomic dsDNA for CFTR
3849+10kbCRT (1 bp A–C mismatch) in the presence of
500 nM YOYO-1 and 45 mM TMA-Cl. The emission values
giving rise to Supplementary Figure S6 data are shown. The
specificity of the triplex assay in detecting CFTR 3849+10kbCRT
in mismatched triplexes is demonstrated in reaction mixtures
containing 500 nM YOYO-1 and 45 mM TMA-Cl.
Found at: doi:10.1371/journal.pone.0000305.s018 (0.05 MB
DOC)
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